Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02145949 · ClinicalTrials.gov registry record · Phase 2

Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults

A Phase 2 study, sponsored by University of Oregon.

Completed
Registry status
Phase 2
Development phase
80
Enrollment target

NCT02145949: Completed Phase 2 study, sponsored by University of Oregon.

NCT02145949 is a Phase 2 study that has completed, run by University of Oregon. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02145949, a Phase 2 study, has completed, sponsored by University of Oregon.

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target

Study Summary

As a function of the growing population of older adults, an estimated 3.48 million total knee arthroplasty (TKA) procedures will be performed annually in the U.S. by 2030. Despite the near-universal success of this surgery in mitigating chronic knee pain, TKA is not successful in restoring long-term physical function in older adults, primarily because of quadriceps muscle atrophy, which explains 77% of the strength deficits. Overall, strength and functional mobility in TKA patients is 30-50% below age-matched healthy controls. Functional tasks such as stair-climbing remain a clinical problem for 75% of patients following TKA. Muscle atrophy occurs in both operative and non-operative legs, and is essentially permanent for older patients because of their impaired ability to increase muscle mass. The purpose of this clinical research is to determine the effects of essential amino acid (EAA) supplementation on muscle mass, strength, and functional mobility following TKA in older adults. Based on strong preliminary data, the investigators hypothesize that twice-daily ingestion of 23 g of EAA for 1 wk before through 6 wk after TKA will increase basal rates of muscle protein synthesis via inactivation of catabolic signaling, and up-regulation of anabolic and cyto-protective proteins. The investigators further hypothesize that short-term atrophy prevention and accelerated return of functional mobility will lead to longer-term structural and functional adaptations, and improved quality of life in older TKA patients vs. Placebo. Identifying the mechanisms up-regulated by EAA treatment that preserve muscle volume and mobility will have a major impact on rehabilitation science. This study will accomplish two specific aims: (1) determine if EAA elevates basal rates of muscle protein synthesis by up-regulating anabolic pathways and cyto-protective proteins, and inactivating catabolic pathways in the short term vs. Placebo and (2) determine if short-term prevention of atrophy, wea

Primary Outcome

MRI of the bilateral lower extremities was performed utilizing a Siemens 3T Skyra to measure muscle volume in Arbitrary Units (AU). Low values = low volume. High values = higher volume. Dixon pulse sequence optimized for imaging near metal implants was used to capture T1-weighted, water, and fat images of the mid-thigh region. MRI of the bilateral lower extremities was performed utilizing a Siemens 3T Skyra (UO Lewis Center for Neuroimaging). Dixon pulse sequence optimized for imaging near me

Interventions

  • DRUG Essential Amino Acids (EAA)
  • DRUG Placebo (Alanine)

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2014-12
Est. Completion 2020-02
Phase Phase 2
University of Oregon

63 total trials

What the finished NCT02145949 record still lists

NCT02145949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).

The record links to 0 conditions, and to 2 interventions - of which Essential Amino Acids (EAA) is the first listed.

NCT02145949 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02145949 about?

NCT02145949 is a clinical study titled "Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults". As a function of the growing population of older adults, an estimated 3.48 million total knee arthroplasty (TKA) procedures will be performed annually in the U.S. by 2030. Despite the near-universal success of this surgery in mitigating chronic knee pain, TKA is not successful in restoring long-term...

What is the current status of trial NCT02145949?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2014-12. Estimated completion is 2020-02.

What interventions are being tested in trial NCT02145949?

The interventions under investigation include: Essential Amino Acids (EAA) (DRUG), Placebo (Alanine) (DRUG).

Who is sponsoring clinical trial NCT02145949?

This trial is sponsored by University of Oregon, which has 63 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02145949's enrollment target sits among peer trials

80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02145949, the US trial registry maintained by the National Library of Medicine. NCT02145949 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.